➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,939,519

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,939,519 protect, and when does it expire?

Patent 7,939,519 protects MAYZENT and is included in one NDA.

This patent has ninety-five patent family members in thirty-four countries.

Summary for Patent: 7,939,519
Title:Immunosuppresant compounds and compositions
Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
Inventor(s): Pan; Shifeng (San Diego, CA), Gao; Wenqi (San Diego, CA), Gray; Nathanael S (San Diego, CA), Mi; Yuan (San Diego, CA), Fan; Yi (Poway, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/024,992
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,939,519

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MAYZENT siponimod fumaric acid TABLET;ORAL 209884-001 Mar 26, 2019 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Novartis MAYZENT siponimod fumaric acid TABLET;ORAL 209884-002 Mar 26, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.